These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 29393340)

  • 61. Targeted molecular therapy for neuroblastoma: the ARF/MDM2/p53 axis.
    Kim E; Shohet J
    J Natl Cancer Inst; 2009 Nov; 101(22):1527-9. PubMed ID: 19903809
    [No Abstract]   [Full Text] [Related]  

  • 62. Neuroblastoma models for insights into tumorigenesis and new therapies.
    Kiyonari S; Kadomatsu K
    Expert Opin Drug Discov; 2015 Jan; 10(1):53-62. PubMed ID: 25345447
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The long non-coding RNA GAS5 differentially regulates cell cycle arrest and apoptosis through activation of BRCA1 and p53 in human neuroblastoma.
    Mazar J; Rosado A; Shelley J; Marchica J; Westmoreland TJ
    Oncotarget; 2017 Jan; 8(4):6589-6607. PubMed ID: 28035057
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
    Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
    Xiong J; Yang Q; Li J; Zhou S
    Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
    [TBL] [Abstract][Full Text] [Related]  

  • 66. P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis.
    Mahfoudhi E; Lordier L; Marty C; Pan J; Roy A; Roy L; Rameau P; Abbes S; Debili N; Raslova H; Chang Y; Debussche L; Vainchenker W; Plo I
    Oncotarget; 2016 May; 7(22):31980-92. PubMed ID: 26959882
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment.
    Hoffman-Luca CG; Yang CY; Lu J; Ziazadeh D; McEachern D; Debussche L; Wang S
    PLoS One; 2015; 10(6):e0128807. PubMed ID: 26070072
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Nutlin-3a selects for cells harbouring TP53 mutations.
    Kucab JE; Hollstein M; Arlt VM; Phillips DH
    Int J Cancer; 2017 Feb; 140(4):877-887. PubMed ID: 27813088
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse.
    Carr J; Bell E; Pearson AD; Kees UR; Beris H; Lunec J; Tweddle DA
    Cancer Res; 2006 Feb; 66(4):2138-45. PubMed ID: 16489014
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.
    Michaelis M; Rothweiler F; Agha B; Barth S; Voges Y; Löschmann N; von Deimling A; Breitling R; Doerr HW; Rödel F; Speidel D; Cinatl J
    Cell Death Dis; 2012 Apr; 3(4):e294. PubMed ID: 22476102
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Reactivation of p53 via MDM2 inhibition.
    Kim ES; Shohet JM
    Cell Death Dis; 2015 Oct; 6(10):e1936. PubMed ID: 26492369
    [No Abstract]   [Full Text] [Related]  

  • 72. Effect of low doses of actinomycin D on neuroblastoma cell lines.
    Cortes CL; Veiga SR; Almacellas E; Hernández-Losa J; Ferreres JC; Kozma SC; Ambrosio S; Thomas G; Tauler A
    Mol Cancer; 2016 Jan; 15():1. PubMed ID: 26728659
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
    Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
    Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
    [TBL] [Abstract][Full Text] [Related]  

  • 74.
    McNerney KO; Karageorgos S; Ferry GM; Wolpaw AJ; Burudpakdee C; Khurana P; Toland CN; Vemu R; Vu A; Hogarty MD; Bassiri H
    Oncoimmunology; 2022; 11(1):2075204. PubMed ID: 35646475
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib.
    Berberich A; Kessler T; Thomé CM; Pusch S; Hielscher T; Sahm F; Oezen I; Schmitt LM; Ciprut S; Hucke N; Ruebmann P; Fischer M; Lemke D; Breckwoldt MO; von Deimling A; Bendszus M; Platten M; Wick W
    Clin Cancer Res; 2019 Jan; 25(1):253-265. PubMed ID: 30274984
    [TBL] [Abstract][Full Text] [Related]  

  • 76. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
    Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
    J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage.
    Bell E; Premkumar R; Carr J; Lu X; Lovat PE; Kees UR; Lunec J; Tweddle DA
    Cell Cycle; 2006 Nov; 5(22):2639-47. PubMed ID: 17172827
    [TBL] [Abstract][Full Text] [Related]  

  • 78. PRIMA-1
    Mlakar V; Jurkovic Mlakar S; Lesne L; Marino D; Rathi KS; Maris JM; Ansari M; Gumy-Pause F
    J Exp Clin Cancer Res; 2019 Feb; 38(1):69. PubMed ID: 30755224
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The interaction between FAK, MYCN, p53 and Mdm2 in neuroblastoma.
    Waters AM; Beierle EA
    Anticancer Agents Med Chem; 2014 Jan; 14(1):46-51. PubMed ID: 24041229
    [TBL] [Abstract][Full Text] [Related]  

  • 80. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.
    Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G
    Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.